Sun Pharmaceutical Industries
Acme Plaza
Andheri Kurla Road
Andheri (East)
Mumbai
400 059
Tel: 91-22-821-12-88
Fax: 91-22-821-20-10
Website: http://www.sunpharma.com/
Email: corpcomm@sunpharma.com
220 articles with Sun Pharmaceutical Industries
-
Although it was relatively quiet in COVID-19-related clinical trials, there was plenty of other clinical trial news. Here’s a look.
-
Sun Pharma Presents Phase 3 Data for WINLEVI® (clascoterone) cream 1% for the Topical Treatment of Acne Vulgaris at the AAD Annual Meeting
3/25/2022
Sun Pharmaceutical Industries Limited today announced that the company's U.S. subsidiary presented data from two pivotal Phase 3 clinical trials of WINLEVI (clascoterone) cream 1% for the topical treatment of acne vulgaris (acne).
-
Sun Pharma to Present Clinical Data Abstracts for ILUMYA® (tildrakizumab-asmn) in Patients with Moderate-to-Severe Plaque Psoriasis at 2022 AAD Annual Meeting
3/24/2022
Sun Pharmaceutical Industries Inc., USA (Sun Pharma) today announced that five data abstracts for ILUMYA will be presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting, taking place March 25-29.
-
Cipher Pharmaceuticals Announces Extension of Distribution and Supply Agreement with Sun Pharmaceutical Industries Inc.
3/10/2022
Cipher Pharmaceuticals Inc. announced that it has entered into a second amended and restated distribution and supply agreement with Sun Pharmaceutical Industries, Inc., a wholly owned subsidiary company of Sun Pharmaceutical Industries Limited, India.
-
Sun Pharma launches (Pr)CEQUA™ (cyclosporine ophthalmic solution 0.09% w/v), the first dry eye treatment with nanomicellar (NCELL™) technology*, in Canada
1/27/2022
Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited "Sun Pharma" and includes its subsidiaries and/or associate companies), announced the launch of CEQUA, a new treatment for Canadians living with dry eye disease.
-
Sun Pharma and Cassiopea announce the expiry of the HSR Act process and the successful consummation of their Winlevi® (clascoterone cream 1%) agreement
8/31/2021
Sun Pharmaceutical Industries Limited today announced the expiration of the applicable waiting period under the US Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act)
-
Sun Pharma and Cassiopea SpA Announce Signing of License and Supply Agreements for Winlevi® (clascoterone cream 1%) in US and Canada
7/26/2021
Sun Pharmaceutical Industries Ltd., "Sun Pharma" and includes its subsidiaries and/or associate companies) and Cassiopea SpA, a specialty pharmaceutical company developing and preparing to commercialize prescription drugs with novel mechanisms of action to address long-standing essential dermatological conditions, announced the signing of License and Supply Agreements for Winlevi® in the United States and Canada.
-
Here’s a look at some of the top COVID-19-related stories for today.
-
Corcept Therapeutics Settles Patent Litigation with Sun Pharmaceutical
6/15/2021
Corcept Therapeutics Incorporated today announced that it has entered into an agreement with Sun Pharmaceutical Industries Limited and related entities ("Sun") resolving patent litigation related to Korlym.
-
Sun Pharma to Present Clinical Data Abstracts for ILUMYA® (tildrakizumab-asmn) in Patients with Moderate-to-Severe Plaque Psoriasis at the AAD Virtual Meeting Experience 2021
4/22/2021
The data abstracts to be presented at AAD VMX reinforce that ILUMYA is a long-lasting biologic treatment choice for patients with moderate-to-severe plaque psoriasis through five years of continuous treatment.
-
Parents are Very Worried About the Effects of Severe Acne on their Teenage Children as Reported in a New Survey
4/7/2021
Findings reflect heightened stress on families as teens cope with isolation and embarrassment; remote schooling eases some worries but exacerbates others
-
Sun Pharma Announces Drizalma Sprinkle™ (duloxetine delayed-release capsules) is Now Covered by Most Medicare Part D Plans
3/9/2021
Coverage for novel formulation of duloxetine now offered to 91% of lives in top 10 Medicare Part D plans Broader access to Drizalma Sprinkle™ reinforces Sun Pharma's commitment to the 40% of American adults who cannot or will not swallow solid medication forms
-
Sun Pharma Launches Website for its Long-Term Care Portfolio in the U.S.
2/25/2021
New website highlights the efficacy and safety profile for each product, while also educating healthcare providers and patients about our intent to mitigate risks associated with improper medication manipulation
-
Sun Pharma Announces 5-Year Sustained Efficacy and Safety Results for ILUMYA® (tildrakizumab-asmn) in Patients with Moderate-to-Severe Plaque Psoriasis
10/31/2020
ILUMYA is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials in moderate-to-severe plaque psoriasis
-
Sun Pharmaceutical Industries, Inc. Issues Voluntary Nationwide Recall of RIOMET ER™ (metformin hydrochloride for extended-release oral suspension) Due to N-Nitrosodimethylamine (NDMA) Content Above the Acceptable Daily Intake (ADI) Limit
9/23/2020
Sun Pharmaceutical Industries, Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Ltd. is voluntarily recalling one lot of RIOMET ER™, 500 mg per 5 mL to the consumer level.
-
Orexo commences patent infringement litigation against Sun Pharmaceutical
9/14/2020
Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces it has filed a patent infringement action in the United States District Court for the District of New Jersey with docket number 3:20-cv-12588, against Sun Pharmaceutical Industries Limited, Sun Pharma Global FZE, Sun Pharma Global, Inc., and Sun Pharmaceutical Indu
-
Orexo receives paragraph IV Notice Letter for ZUBSOLV® in the US
8/10/2020
Orexo AB, announces it has received a "paragraph IV" patent certification notice from Sun Pharmaceutical Industries Limited.
-
Sun Pharma Presents ODOMZO® and LEVULAN® KERASTICK® + BLU-U® Data, Offering Clinical Insights for Treating People with or at Risk of Skin Cancer
6/12/2020
Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" including its subsidiaries and/or associate companies) today announced that one of its wholly-owned subsidiaries presented data analyses for two of its specialty medicines – ODOMZO® (sonidegib) and LEVULAN® KERASTICK®
-
Sun Pharma Announces Long-term Insights into the Clinical Use of ILUMYA™ (tildrakizumab-asmn) in a Cross Section of People Living with Moderate-to-Severe Plaque Psoriasis
6/12/2020
Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" including its subsidiaries and/or associate companies) today announced that one of its wholly owned subsidiaries presented further evidence of the long-term use and cost-effectiveness of ILUMYATM
-
Sun Pharma Plans to Present Clinical Insights from 25 Data Abstracts Across its Dermatology Portfolio at the 2020 AAD Virtual Meeting Experience
6/11/2020
The breadth of continued research in plaque psoriasis, psoriatic arthritis, basal cell carcinoma, and actinic keratoses underscores Sun Pharma's commitment to dermatology HCPs and patients [11-June-2020] PRINCETON, N.J. , June 11, 2020 /PRNewswire/ -- Sun Pharmaceutical Industries Inc., USA (SPII) "Sun Pharma" today announced 25 data abstracts from its dermatology p